Latest Report - Acne Vulgaris - Pipeline Review, H1 2014

411 views
298 views

Published on

Acne Vulgaris - Pipeline Review, H1 2014 @ http://www.researchmoz.us/acne-vulgaris-pipeline-review-h1-2014-report.html

This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
411
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Latest Report - Acne Vulgaris - Pipeline Review, H1 2014

  1. 1. Acne Vulgaris - Pipeline Review, H1 2014 Acne Vulgaris - Pipeline Review, H1 2014 Summary Global Markets Directs, Acne Vulgaris - Pipeline Review, H1 2014, provides an overview of the Acne Vulgariss therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acne Vulgaris and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acne Vulgaris products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acne Vulgaris pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table Of Contents table Of Contents 2 list Of Tables 8 list Of Figures 9 introduction 10 global Markets Direct Report Coverage 10 acne Vulgaris Overview 11 therapeutics Development 12 pipeline Products For Acne Vulgaris - Overview 12 pipeline Products For Acne Vulgaris - Comparative Analysis 13 acne Vulgaris - Therapeutics Under Development By Companies 14 acne Vulgaris - Therapeutics Under Investigation By Universities/institutes 18 acne Vulgaris - Pipeline Products Glance 19 late Stage Products 19 clinical Stage Products 20 Acne Vulgaris - Pipeline Review, H1 2014
  2. 2. early Stage Products 21 unknown Stage Products 22 acne Vulgaris - Products Under Development By Companies 23 acne Vulgaris - Products Under Investigation By Universities/institutes 25 acne Vulgaris - Companies Involved In Therapeutics Development 26 boehringer Ingelheim Gmbh 26 photocure Asa 27 valeant Pharmaceuticals International, Inc. 28 glaxosmithkline Plc 29 photopharmica Limited 30 galderma S.a. 31 toyama Chemical Co., Ltd. 32 anticancer, Inc. 33 xoma Corporation 34 quest Pharmatech Inc. 35 provectus Biopharmaceuticals, Inc. 36 phosphagenics Limited 37 foamix Ltd. 38 androscience Corporation 39 hygeia Therapeutics, Inc. 40 elorac, Inc. 41 cutanea Life Sciences 42 braintree Laboratories, Inc. 43 maruho Co., Ltd. 44 sol-gel Technologies Ltd. 45 ensoltek Co., Ltd. 46 ausio Pharmaceuticals, Llc 47 xbiotech Usa, Inc. 48 advancell 49 delenex Therapeutics Ag 50 dermira Inc. 51 dignity Sciences Ltd. 52 biomar Microbial Technologies 53 thesan Pharmaceuticals, Inc. 54 origimm E.u. 55 acne Vulgaris - Therapeutics Assessment 56 assessment By Monotherapy Products 56 assessment By Combination Products 57 assessment By Target 58 assessment By Mechanism Of Action 61 assessment By Route Of Administration 64 assessment By Molecule Type 66 drug Profiles 68 (adapalene + Benzoyl Peroxide) - Drug Profile 68 product Description 68 mechanism Of Action 68 r&d Progress 68 ozenoxacin - Drug Profile 69 product Description 69 mechanism Of Action 69 r&d Progress 69 benzoyl Peroxide - Drug Profile 71 product Description 71 mechanism Of Action 71 r&d Progress 71 e-10215 - Drug Profile 72 product Description 72 mechanism Of Action 72 r&d Progress 72 omiganan Pentahydrochloride - Drug Profile 73 product Description 73 mechanism Of Action 73 r&d Progress 73 tretinoin - Drug Profile 75 product Description 75 mechanism Of Action 75 r&d Progress 75 ascj-9 - Drug Profile 76 Acne Vulgaris - Pipeline Review, H1 2014
  3. 3. product Description 76 mechanism Of Action 76 r&d Progress 76 aus-131 - Drug Profile 77 product Description 77 mechanism Of Action 77 r&d Progress 77 methyl Aminolevulinate - Drug Profile 79 product Description 79 mechanism Of Action 79 r&d Progress 79 gevokizumab - Drug Profile 81 product Description 81 mechanism Of Action 81 r&d Progress 81 cb-0301 - Drug Profile 84 product Description 84 mechanism Of Action 84 r&d Progress 84 minocycline - Drug Profile 86 product Description 86 mechanism Of Action 86 r&d Progress 86 drm-01 - Drug Profile 88 product Description 88 mechanism Of Action 88 r&d Progress 88 bli-1100 - Drug Profile 89 product Description 89 mechanism Of Action 89 r&d Progress 89 cd2475/101 - Drug Profile 90 product Description 90 mechanism Of Action 90 r&d Progress 90 jnj-10229570-aaa - Drug Profile 91 product Description 91 mechanism Of Action 91 r&d Progress 91 ra-18c3 - Drug Profile 93 product Description 93 mechanism Of Action 93 r&d Progress 93 cd-5789 - Drug Profile 95 product Description 95 mechanism Of Action 95 r&d Progress 95 nvn-1000 - Drug Profile 96 product Description 96 mechanism Of Action 96 r&d Progress 96 onabotulinumtoxina - Drug Profile 97 product Description 97 mechanism Of Action 97 r&d Progress 97 ark-e021 - Drug Profile 98 product Description 98 mechanism Of Action 98 r&d Progress 98 sl-017 - Drug Profile 99 product Description 99 mechanism Of Action 99 r&d Progress 99 gsk-1940029 - Drug Profile 101 product Description 101 mechanism Of Action 101 r&d Progress 101 fx-125-l - Drug Profile 102 Acne Vulgaris - Pipeline Review, H1 2014
  4. 4. product Description 102 mechanism Of Action 102 r&d Progress 102 ph-10 - Drug Profile 104 product Description 104 mechanism Of Action 104 r&d Progress 104 hyg-440 - Drug Profile 106 product Description 106 mechanism Of Action 106 r&d Progress 106 sgt-tn-65 - Drug Profile 107 product Description 107 mechanism Of Action 107 r&d Progress 107 sgt-sz-91 - Drug Profile 108 product Description 108 mechanism Of Action 108 r&d Progress 108 ans-29 - Drug Profile 109 product Description 109 mechanism Of Action 109 r&d Progress 109 ad-037 - Drug Profile 110 product Description 110 mechanism Of Action 110 r&d Progress 110 drug For Acne - Drug Profile 111 product Description 111 mechanism Of Action 111 r&d Progress 111 anti Acne Vaccine - Drug Profile 112 product Description 112 mechanism Of Action 112 r&d Progress 112 small Molecule For Acne - Drug Profile 113 product Description 113 mechanism Of Action 113 r&d Progress 113 ds-109 - Drug Profile 114 product Description 114 mechanism Of Action 114 r&d Progress 114 drugs To Inhibit Gnrh Receptor For Dermatology, Hormonal Disorders, Non Malignant Disorders, Oncology And Women Health - Drug Profile 115 product Description 115 mechanism Of Action 115 r&d Progress 115 salicylic Acid - Drug Profile 116 product Description 116 mechanism Of Action 116 r&d Progress 116 lipo-4ma - Drug Profile 117 product Description 117 mechanism Of Action 117 r&d Progress 117 dlx-2323 - Drug Profile 118 product Description 118 mechanism Of Action 118 r&d Progress 118 peptide To Disrupt Bacterial Cell Membrane And Cell Wall For Acne And Skin Cancer - Drug Profile 119 product Description 119 mechanism Of Action 119 r&d Progress 119 sharon-4000 - Drug Profile 120 product Description 120 mechanism Of Action 120 r&d Progress 120 small Molecule For Acne - Drug Profile 121 Acne Vulgaris - Pipeline Review, H1 2014
  5. 5. product Description 121 mechanism Of Action 121 r&d Progress 121 drugs For Acne - Drug Profile 122 product Description 122 mechanism Of Action 122 r&d Progress 122 acne Vaccine - Drug Profile 123 product Description 123 mechanism Of Action 123 r&d Progress 123 acne Vulgaris - Recent Pipeline Updates 124 acne Vulgaris - Dormant Projects 136 acne Vulgaris - Discontinued Products 137 acne Vulgaris - Product Development Milestones 138 featured News & Press Releases 138 mar 19, 2014: Novan Announces Positive Phase 2 Results For Novel Acne Treatment 138 jun 25, 2013: Xoma's Development Partner Servier Launches Proof-of-concept Clinical Program For Gevokizumab 138 feb 28, 2013: Meda's Acnex Receives Registration Approval In Europe 139 feb 28, 2013: Novan Therapeutics On Path To Develop First Topical Acne Treatment 140 feb 19, 2013: Galderma's Epiduo Gel Obtains Fda Approval To Treat Acne In Children As Young As Nine Years Old 140 jan 07, 2013: Xoma Announces Positive Interim Results From Gevokizumab Phase Ii Study For Moderate To Severe Acne Vulgaris 141 dec 12, 2012: Xbiotech Announces Positive Phase Ii Clinical Trial Results For Mabp1 In Acne Vulgaris 142 jul 30, 2012: Watson Confirms Epiduo Gel Patent Challenge 143 jan 13, 2012: Photocure Completes Enrollment In Visonac Phase Iib Study For Acne Treatment 143 dec 21, 2011: Xoma Initiates Gevokizumab Phase Ii Study For Moderate To Severe Acne Vulgaris 143 appendix 145 methodology 145 coverage 145 secondary Research 145 primary Research 145 expert Panel Validation 145 contact Us 146 disclaimer 146 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Acne Vulgaris - Pipeline Review, H1 2014

×